Cargando…

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands

PURPOSE: The fixed-dose dual bronchodilator combination (FDC) of tiotropium and olodaterol showed increased effectiveness regarding lung function and health-related quality of life in patients with chronic obstructive pulmonary disease (COPD) compared with the use of its mono-components. Yet, while...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Boven, Job FM, Kocks, Janwillem WH, Postma, Maarten J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036592/ https://www.ncbi.nlm.nih.gov/pubmed/27703341 http://dx.doi.org/10.2147/COPD.S114738

Ejemplares similares

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
por: Lan, Ying, et al.
Publicado: (2023)

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G.
Publicado: (2018)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO(®) Trials
por: Rabe, Klaus F., et al.
Publicado: (2020)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
por: Muruganandan, Sanjeevan, et al.
Publicado: (2015)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
por: Buhl, Roland, et al.
Publicado: (2015)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
por: Pelaia, Girolamo, et al.
Publicado: (2015)

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
por: Derom, Eric, et al.
Publicado: (2019)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
Publicado: (2018)

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
por: O'Donnell, Denis E., et al.
Publicado: (2017)

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study
por: Hoogendoorn, Martine, et al.
Publicado: (2021)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
por: Tebboth, Abigail, et al.
Publicado: (2016)

Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD
por: Maltais, François, et al.
Publicado: (2019)

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
por: Singh, Dave, et al.
Publicado: (2016)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
por: Miravitlles, Marc, et al.
Publicado: (2017)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
por: Sauer, Rüdiger, et al.
Publicado: (2016)

Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol
por: van Boven, Job F M, et al.
Publicado: (2015)

Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO(®) and OTEMTO(®) Studies
por: Buhl, Roland, et al.
Publicado: (2020)

Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis
por: Muro, Shigeo, et al.
Publicado: (2021)

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
por: Hoogendoorn, Martine, et al.
Publicado: (2019)

Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients
por: Valipour, Arschang, et al.
Publicado: (2019)

Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators
por: Nicolini, Antonello
Publicado: (2012)

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO(®) study
por: Minakata, Yoshiaki, et al.
Publicado: (2019)

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies
por: Ferguson, Gary T., et al.
Publicado: (2020)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

Differential Response to 12 Weeks of Once-Daily Tiotropium/Olodaterol Fixed Dose Combination in Patients with COPD: A Multidimensional Response Profiling in the TORRACTO Study
por: Posthuma, Rein, et al.
Publicado: (2023)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat(®) in patients with COPD in a real-world clinical setting
por: Steinmetz, Karl-Otto, et al.
Publicado: (2019)

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO(®) study [Erratum]
Publicado: (2019)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study
por: Gillissen, Adrian, et al.
Publicado: (2021)

Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database
por: Quint, Jennifer K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0pms0f7p3v4dtgk10f855b37o8